289 related articles for article (PubMed ID: 35978227)
1. New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease.
Liu Y; Liu T; Zhao X; Gao Y
Cell Mol Life Sci; 2022 Aug; 79(9):486. PubMed ID: 35978227
[TBL] [Abstract][Full Text] [Related]
2. Environmental Chemical Contribution to the Modulation of Bile Acid Homeostasis and Farnesoid X Receptor Signaling.
Taylor RE; Bhattacharya A; Guo GL
Drug Metab Dispos; 2022 Apr; 50(4):456-467. PubMed ID: 34759011
[TBL] [Abstract][Full Text] [Related]
3. Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases.
Yang T; Khan GJ; Wu Z; Wang X; Zhang L; Jiang Z
Drug Discov Today; 2019 Jan; 24(1):112-128. PubMed ID: 30244079
[TBL] [Abstract][Full Text] [Related]
4. JiaGaSongTang improves chronic cholestasis via enhancing FXR-mediated bile acid metabolism.
He X; Zhou Y; Yu J; Huang Q; Chen Z; Xiao R; Liu C; Gui S; Xiong T
Phytomedicine; 2024 Jun; 128():155347. PubMed ID: 38493717
[TBL] [Abstract][Full Text] [Related]
5. New therapeutic concepts in bile acid transport and signaling for management of cholestasis.
Trauner M; Fuchs CD; Halilbasic E; Paumgartner G
Hepatology; 2017 Apr; 65(4):1393-1404. PubMed ID: 27997980
[TBL] [Abstract][Full Text] [Related]
6. Bile Acids in Cholestasis and its Treatment.
Arab JP; Cabrera D; Arrese M
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s53-s57. PubMed ID: 29080340
[TBL] [Abstract][Full Text] [Related]
7. Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury.
Petrescu AD; DeMorrow S
Cells; 2021 Jul; 10(8):. PubMed ID: 34440614
[TBL] [Abstract][Full Text] [Related]
8. Gardenia extract protects against intrahepatic cholestasis by regulating bile acid enterohepatic circulation.
Qin S; Tian J; Zhao Y; Wang L; Wang J; Liu S; Meng J; Wang F; Liu C; Han J; Pan C; Zhang Y; Yi Y; Li C; Liu M; Liang A
J Ethnopharmacol; 2024 Jan; 319(Pt 1):117083. PubMed ID: 37634748
[TBL] [Abstract][Full Text] [Related]
9. Bile acid transporters and regulatory nuclear receptors in the liver and beyond.
Halilbasic E; Claudel T; Trauner M
J Hepatol; 2013 Jan; 58(1):155-68. PubMed ID: 22885388
[TBL] [Abstract][Full Text] [Related]
10. Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease.
Pereira-Fantini PM; Lapthorne S; Joyce SA; Dellios NL; Wilson G; Fouhy F; Thomas SL; Scurr M; Hill C; Gahan CG; Cotter PD; Fuller PJ; Hardikar W; Bines JE
J Hepatol; 2014 Nov; 61(5):1115-25. PubMed ID: 24999016
[TBL] [Abstract][Full Text] [Related]
11. Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress.
Wang MQ; Zhang KH; Liu FL; Zhou R; Zeng Y; Chen AL; Yu Y; Xia Q; Zhu CC; Lin CZ
Phytomedicine; 2024 Jan; 122():155124. PubMed ID: 38014837
[TBL] [Abstract][Full Text] [Related]
12. Melatonin improves cholestatic liver disease via the gut-liver axis.
Liu X; Li J; Shi M; Fu J; Wang Y; Kang W; Liu J; Zhu F; Huang K; Chen X; Liu Y
J Pineal Res; 2024 Jan; 76(1):e12929. PubMed ID: 38047407
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling.
Di Ciaula A; Bonfrate L; Baj J; Khalil M; Garruti G; Stellaard F; Wang HH; Wang DQ; Portincasa P
Nutrients; 2022 Nov; 14(23):. PubMed ID: 36500979
[TBL] [Abstract][Full Text] [Related]
14. Bile Acids and GPBAR-1: Dynamic Interaction Involving Genes, Environment and Gut Microbiome.
Portincasa P; Di Ciaula A; Garruti G; Vacca M; De Angelis M; Wang DQ
Nutrients; 2020 Nov; 12(12):. PubMed ID: 33266235
[TBL] [Abstract][Full Text] [Related]
15. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
[TBL] [Abstract][Full Text] [Related]
16. The Enterokine Fibroblast Growth Factor 15/19 in Bile Acid Metabolism.
Cariello M; Piglionica M; Gadaleta RM; Moschetta A
Handb Exp Pharmacol; 2019; 256():73-93. PubMed ID: 31123830
[TBL] [Abstract][Full Text] [Related]
17. Intestinal microbiota drives cholestasis-induced specific hepatic gene expression patterns.
Juanola O; Hassan M; Kumar P; Yilmaz B; Keller I; Simillion C; Engelmann C; Tacke F; Dufour JF; De Gottardi A; Moghadamrad S
Gut Microbes; 2021; 13(1):1-20. PubMed ID: 33847205
[TBL] [Abstract][Full Text] [Related]
18. A Physiology-Based Model of Bile Acid Distribution and Metabolism Under Healthy and Pathologic Conditions in Human Beings.
Voronova V; Sokolov V; Al-Khaifi A; Straniero S; Kumar C; Peskov K; Helmlinger G; Rudling M; Angelin B
Cell Mol Gastroenterol Hepatol; 2020; 10(1):149-170. PubMed ID: 32112828
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling.
Schneider KM; Candels LS; Hov JR; Myllys M; Hassan R; Schneider CV; Wahlström A; Mohs A; Zühlke S; Liao L; Elfers C; Kilic K; Henricsson M; Molinaro A; Hatting M; Zaza A; Drasdo D; Frissen M; Devlin AS; Gálvez EJC; Strowig T; Karlsen TH; Hengstler JG; Marschall HU; Ghallab A; Trautwein C
Nat Metab; 2021 Sep; 3(9):1228-1241. PubMed ID: 34552267
[TBL] [Abstract][Full Text] [Related]
20. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology.
Fuchs CD; Trauner M
Nat Rev Gastroenterol Hepatol; 2022 Jul; 19(7):432-450. PubMed ID: 35165436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
